ABSTRACT Introduction: Metastatic colorectal cancer is rarely curable. Improving quality of life is therefore a key treatment goal. We report quality of life for patients with RAS wild-type metastatic colorectal cancer in the PRIME study. Methods: A randomised phase 3 open-label study of first-line panitumumab+FOLFOX4 vs FOLFOX4 enrolled adults with untreated metastatic colorectal cancer and an Eastern Cooperative Oncology Group performance status of 0–2. This analysis includes patients with wildtype RAS tumours (n=505). Quality of life ( prespecified end point) was assessed using the EuroQoL 5-domain health state index and overall health rating in all patients and by early tumour shrinkage status (≥30% reduction in size by week 8; exploratory end point). Differences in quality of life were assessed using analysis of covariance and a mixed-effect piecewise linear model, and were also analysed by skin toxicity severity. Results: There were no statistically significant differences between treatment arms from baseline to progression or to discontinuation. Grade 3+ skin toxicity was reported by 38% of patients receiving panitumumab+FOLFOX4 and 2% receiving FOLFOX4 alone. There were no significant differences in qualityof life between patients with grade 0–2 skin toxicity and those with grade 3+ skin toxicity. More patientsreceiving panitumumab+FOLFOX4 vs FOLFOX4 had early tumour shrinkage ( p<.001). In patients with tumour symptoms at baseline, there were statistically significant improvements in quality of life in those with early tumour shrinkage versus those without earlytumour shrinkage. Conclusions: Addition of panitumumab to FOLFOX4 in first-line therapy for metastatic colorectal cancer prolongs survival and has no negative effect on overall quality of life compared with FOLFOX4 alone. Specific quality of life assessments for skin toxicity should be included in study designs to better define the direct effect of these adverse events.
|Titolo:||Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma : results from a randomised controlled trial|
SIENA, SALVATORE (Primo) (Corresponding)
|Parole Chiave:||colorectal cancer, quality of life, panitumumab|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||31-mar-2016|
|Digital Object Identifier (DOI):||10.1136/ esmoopen-2016-000041|
|Appare nelle tipologie:||01 - Articolo su periodico|